NCT02485392

Brief Summary

A single-blinded randomized clinical trial (RCT) designed to compare Single-Site robot-assisted with single-incision laparoscopic cholecystectomy. The study directly compares both surgical approaches in a cohort of 60 patients (30 patients in each arm) with benign gallbladder disease from the Department of Surgery at the Cantonal Hospital of Winterthur (Kantonsspital Winterthur) in Switzerland. The primary endpoint of the study is the surgeon's physical and mental stress load at the time of surgery and is assessed by validated Local Experienced Discomfort (LED) and Subjective Mental Effort Questionnaire (SMEQ) visual analogue scales. The secondary endpoints include costs of the procedure, intra-operative blood loss, operating time, intra-operative conversion rate and additional trocar placement, complications, length of hospital stay, Health-Related Quality of Life (HRQoL) and cosmesis. HRQoL and cosmesis will be assessed using the validated Gastrointestinal Quality of Life Index (GIQLI) and the Body Image Questionnaires (BIQ), respectively. The inclusion criteria cover most notably symptomatic cholecystolithiasis, chronic cholecystitis, benign gallbladder polyps and age ≥18 years. The exclusion criteria are, among others, acute cholecystitis, emergency cholecystectomy, previous extensive upper abdominal surgery and suspicion of malignant disease. Non-stratified block randomization (random block sizes 2 and 4) will be used to achieve balance in the allocation of participants to both treatments arms and prevent a premature decoding of the randomization scheme. Hereby, the patient will not be informed about the group assignment until the last outpatient follow-up and only after he/she has completed and returned all required questionnaires (GIQLI and BIQ). The operation will be performed according to the group assignment by senior surgeons only who have a wide experience in both robotic Single-Site and conventional single-incision laparoscopy. All data are recorded safely using the SecuTrialTM program. Sample-size calculations are based on the results of the previously mentioned experimental setup by Schatte et al, utilizing an estimated effect size of 0.8, at a power of 0.8 and an alpha-error level of 0.05, as well as considering a potential additional error margin of 10-15% of the calculations (G-Power 3.1 software, Heinrich-Heine University Duesseldorf/Germany). The estimated total duration of the study is 1.5 years, including the scheduled 1-month and 1-year postoperative follow-up visits. The study will be carried out in accordance with principles enunciated in the current version of the Declaration of Helsinki, the guidelines of Good Clinical Practice (GCP) issued by International Conference on Harmonization (ICH), and Swiss regulatory authority's requirements.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jul 2015

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 19, 2015

Completed
4 months until next milestone

First Posted

Study publicly available on registry

June 30, 2015

Completed
1 day until next milestone

Study Start

First participant enrolled

July 1, 2015

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2016

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2017

Completed
Last Updated

September 9, 2016

Status Verified

September 1, 2016

Enrollment Period

1 year

First QC Date

February 19, 2015

Last Update Submit

September 8, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Surgeon's comfort as measured by LED and SMEQ questionnaires

    1 Day

Secondary Outcomes (9)

  • Intra-operative blood loss

    1 day

  • Operating time

    1 day

  • Intra--operative conversion rate

    1 day

  • Complications

    1 year

  • Length of hospital stay

    until discharge (average of 2 days)

  • +4 more secondary outcomes

Study Arms (2)

Single-Site robot-assisted cholecystectomy

ACTIVE COMPARATOR

Single-Site robot-assisted cholecystectomy

Device: Da Vinci Single Site Robot-Assisted Cholecystectomy

Single-incision laparoscopic cholecystectomy

ACTIVE COMPARATOR

Single-incision laparoscopic cholecystectomy

Device: Single Incision Laparoscopic Cholecystectomy

Interventions

Single-Site robot-assisted cholecystectomy
Single-incision laparoscopic cholecystectomy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient compliance and geographic proximity allow proper preoperative checkup and postoperative follow-up
  • Written informed consent given by the patient
  • Women who are not breastfeeding and are not pregnant
  • Age ≥18 years
  • Symptomatic cholecystolithiasis
  • Chronic cholecystitis
  • Benign gallbladder polyps

You may not qualify if:

  • Significant concomitant diseases making the patient unsuitable for abdominal surgery by the judgement of the physicians involved
  • Peritoneal carcinomatosis or other extensive metastatic disease
  • American Society of Anesthesiologists (ASA) IV and V patients
  • Mental or organic disorders which could interfere with giving informed consent or receiving treatments
  • Contraindications to pneumoperitoneum
  • Suspicion of malignant disease
  • Previous extensive upper abdominal surgery
  • Acute cholecystitis
  • Emergency cholecystectomy
  • Obesity II°---III° (BMI\>35.0 kg/m2)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kantonsspital Winterthur

Winterthur, 8401, Switzerland

Location

Related Publications (2)

  • Grochola LF, Soll C, Zehnder A, Wyss R, Herzog P, Breitenstein S. Robot-assisted versus laparoscopic single-incision cholecystectomy: results of a randomized controlled trial. Surg Endosc. 2019 May;33(5):1482-1490. doi: 10.1007/s00464-018-6430-7. Epub 2018 Sep 14.

  • Grochola LF, Soll C, Zehnder A, Wyss R, Herzog P, Breitenstein S. Robot-assisted single-site compared with laparoscopic single-incision cholecystectomy for benign gallbladder disease: protocol for a randomized controlled trial. BMC Surg. 2017 Feb 9;17(1):13. doi: 10.1186/s12893-017-0206-1.

Study Officials

  • Stefan Breitenstein, MD

    Kantonsspital Winterthur KSW

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 19, 2015

First Posted

June 30, 2015

Study Start

July 1, 2015

Primary Completion

July 1, 2016

Study Completion

July 1, 2017

Last Updated

September 9, 2016

Record last verified: 2016-09

Locations